Among patients with TP53 mutations, the CR rate was 41%, with a 1-year OS of 53%, compared to 83% in patients with wild-type TP53. A Phase III trial is currently underway to further evaluate this triplet combination in newly diagnosed AML (61, 62). This evidence concerns the gene TP53 and acute myeloid leukemia.